Happiness Development Group Ltd (HAPP) 시세

CHART

It's poppin

News

...

...

I'm ready to get happy SM

It’s worth way more than current pps

Way oversold here.

HAPP 2.55 someone said NEWS to make us HAPPY

$HAPP

Got some today at $2.98

Is the fda approval today ~>https://nypost.com/2020/04/02/fda-approves-first-serology-test-for-coronavirus/

* * $HAPP Video Chart 03-25-2020 * *

Link to Video - click here to watch the technical chart video

NANPING, China, March 25, 2020 /PRNewswire/ -- Happiness Biotech Group Limited ((the ", Company", NASDAQ:HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company, together with Fuzhou University, have achieved a breakthrough in developing Covid-19 Testing Kits.
Currently, the main Covid-19 detection method is nucleic acid detection. The average detection takes 5-6 hours, while the misdetection rate is high and the cost is high. In the past two months, the Company has been dedicated to developing a more efficient and affordable testing kit for Covid-19 through its biochemical laboratory that the Company jointly established with School of Bioscience and Engineering, Fuzhou University.
The Company made a breakthrough and successfully developed the colloidal gold testing kit by adopting the antibody detection method. The colloidal gold testing kits innovatively use multiple target tests combined with IgM / IgG tests, which greatly improve the detection sensitivity. The detection rate of IgM antibody in clinical patients is more than 70%, and that of IgG antibody in convalescent patients is more than 90%. The testing kits not only greatly improve the success rate of detection, but also greatly shorten the detection time to 10-15 minutes, while the cost is relatively low compared to the nucleic acid detection.
"We are ready to submit the CFDA certification application next week, and we expect to receive the approval soon since the CFDA has granted emergency approval mechanism for Covid-19 Testing Kits. We also plan to apply for CE certification in Europe and FDA certification in the United States. We are very grateful to the experts of Fuzhou University and the staff of our biochemical laboratory for their hard work. At present, the company has begun to transform the production workshop to prepare for mass production. We believe that through the efforts of companies like us, people all over the world will be able to use more efficient and affordable Covid-19 testing kits in the near future." Mr. Xuezhu Wang, CEO of the Company, proudly stated.

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Anyone in this? Just started a position at $4.6. It has good sales and a nice net profit. Wondering why its trading so low? Do these kind of companies normally only trade at less than 2x sales?

$HAPP: Loading up on this now.........


This pullback is a GIFT.


People are gonna be buying this up in CHINA



Now at $4.28


Bounce back to $7 next week again.


Similar bounce like $NNVC from $3 to $17



GO $HAPP

$HAPP: Corporate Presentation


https://www.streetinsider.com/SEC+Filings/Form+FWP+Happiness+Biotech+Group+Filed+by%3A+Happiness+Biotech+Group+Ltd/15930575.html



GO $HAPP

$HAPP: Cordyceps Mycelia





GO $HAPP

$HAPP: Opening position at $5.75



GOOOOoooooooooooooooooooooooooo



Let see it get to $20





GO $HAPP

$HAPP: Opening of Store in Hainan Province


Happiness Biotech Announces the Opening of its First Experience Store in Hainan, China, introducing the Company's 31st Experience Store
NANPING, China, Jan. 6, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today the opening of its first experience store in Hainan, China, which is the Company's 31st experience store.

"Hainan is an important tourism attraction and an ideal travel destination for tourists in winter. With this first store, we gained access to the Hainan market," Mr. Wang Xuezhu, CEO of the Company, continued, "strategically, this is of great importance to the company in the tourism market, especially in winter."

"The experience store model is a unique model we developed mainly targeting the tourism market. In the experience stores, the tourists may learn the history and health benefits of Lucidum and listen to the lectures about our products. In past 3 years, we have established strategic relationship with most of the major travel agents in China. As of March 31, 2019, the Company had a total of 25 experience stores across the country, including Wuyi Montain, Xiamen, Shanghai, Suzhou, Shenyang, Beihai and other major tourism attractions. We are excited to see that the total number of experience stores increased to 31 as of December 31, 2019, and we will continue to evaluate more tourism locations in China and potentially overseas in the near future." Mr. Wang commented.

About Happiness Biotech Group Limited.

Headquartered in Nanping, China, Happiness Biotech Group Limited is an innovative China-based nutraceutical and dietary supplements producer focused on the research, development, manufacturing and marketing of a variety of products made from Chinese herbal extracts and other ingredients. The Company's goal is to provide high-quality products to our consumers. Over the past 14 years, the Company has established a product portfolio consisting of 32 SFDA registered "Blue-Cap" SKUs of nutraceutical and dietary supplements products. For more information, please visit: www.happ.org.cn.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

SOURCE Happiness Biotech Group Limited


For further information: Jiong Bian, Chief Financial Officer, Tel: +86-599-7828808, Email: bianjiong@fjxfl.com

$HAPP: $32Million in Annual Sales


https://finance.yahoo.com/news/happiness-biotech-group-limited-announces-130000759.html



GO $HAPP

$HAPP: NEWS... Sales surge for CoronaVirus drug


Now hitting $7.25






GO $HAPP


********************************************************************


Sales of Cordyceps Mycelia Products Surged over 100% in January
Print
Alert
Happiness Biotech (NASDAQ:HAPP)
Intraday Stock Chart
Today : Tuesday 28 January 2020

Click Here for more Happiness Biotech Charts.
NANPING, China, Jan. 28, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the sales of its Cordyceps mycelia products surged over 100% in January due to the outbreak of the Wuhan Coronavirus.

As of January 27, 2020, revenue from Cordyceps mycelia products has reached over RMB 8 million (approximately USD 1.2 million), 100% higher than December 2019 and 125% higher than November 2019.

Starting from the end of December 2019, China has seen massive outbreaks of the new coronavirus. The demand for products that targeting people with weak immune system has been stronger than ever. The Company obtained the approval for Cordyceps Mycelia Oral Liquid from the China Food and Drug Administration ("CFDA") back in 1997, being among one of the first companies to receive this approval. According to the results of clinical evaluation, Cordyceps Mycelia Oral Liquid regulates humoral and cellular immunity and improves phagocytosis of macrophages, thus improving body resistance and preventing disease. Such clinical evaluation results were approved by CFDA to be included in Cordyceps Mycelia Oral Liquid's product description.

"Since the outbreak of Wuhan coronavirus, the demand for our Cordyceps Mycelia Oral Liquid and other nutritional products has increased dramatically. As a public company and being aware of these demands, we feel it is our responsibility to contribute and respond to people's needs in a time when everyone is doing everything in their power to reduce the impact of this disease. We have requested that our employees continue manufacturing even amidst the Chinese New Year's celebrations. We anticipate the demand will continue to increase over the next several months before the coronavirus is fully under control. We are prepared to increase the production capacity at any moment, if necessary," said Mr. Xuezhu Wang, CEO of the Company.

About Happiness Biotech Group Limited.
Headquartered in Nanping, China, Happiness Biotech Group Limited is an innovative China-based nutraceutical and dietary supplements producer focused on the research, development, manufacturing and marketing of a variety of products made from Chinese herbal extracts and other ingredients. The Company's goal is to provide high-quality products to our consumers. Over the past 14 years, the Company has established a product portfolio consisting of 32 CFDA registered "Blue-Cap" SKUs of nutraceutical and dietary supplements products. For more information, please visit: www.happ.org.cn.

Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Cision View original content:www.prnewswire.com/news-releases/sales-of-cordyceps-mycelia-products-surged-over-100-in-january-300994160.html

SOURCE Happiness Biotech Group Limited


Copyright 2020 PR Newswire